Satellite Symposia at the Society of Pelvic Research "Application of Nanotechnology in the field of Benign Urologic Disease" December 11, 2020

Friday, December 11, 1.00-3.00pm.

Hosted by the NIH P20 Center for "Application of Nanotechnology in the field of Benign Urologic Disease" at the Albert Einstein College of Medicine, NY

1.00-1.10: Kelvin Davies, Ph.D. Director of the NIH P20 Center for "Application of Nanotechnology in the field of Benign Urologic Disease", Albert Einstein College of Medicine, NY. "Introduction".

1.10- 1.40: Keynote Speaker: Daniel Heller, Ph.D. Memorial Sloan Kettering Cancer Center, NY. "Nanomedicines for the treatment of renal disease"

1.40-2.00: Joel Friedman M.D., Ph.D. Project Leader of the NIH P20 Center for "Application of Nanotechnology in the field of Benign Urologic Disease" and Parimala Nacaharaju, Ph.D. Albert Einstein College of Medicine, NY. Albert Einstein College of Medicine, NY. "The "Einstein nanoparticle": background and history, synthesis, physico-chemical characteristics and adaptations to benign urologic disease research".

2.00- 2.20: Kelvin Davies, Ph.D. and Moses Tar, M.D. Albert Einstein College of Medicine, NY. **"Application of nanotechnology to sexual medicine"**.

2.20-2.40: Sylvia Suadicani, Ph.D. Associate Director of NIH P20 Center for "Application of Nanotechnology in the field of Benign Urologic Disease", Albert Einstein College of Medicine, NY. "Nanotechnology applied to development of delivery systems for bladder targeted therapeutics".

2.40-3.00 Invited Speaker: Serkan Karakus, M.D., Johns Hopkins School of Medicine, MD "NO-releasing nanoparticles ameliorate detrusor overactivity in transgenic sickle cell mice via restored NO/ROCK signaling".